Cell Therapeutics' brain cancer drug gets orphan status
Reuters via Yahoo! Maktoob News Tue, 02 Oct 2012 05:52 AM PDT
(Reuters) - Cell Therapeutics Inc said U.S. health regulators granted orphan drug status to its brain cancer drug, sending the company's shares up 26 percent in premarket trading. Orphan status, which is granted by the U.S. Food and Drug Administration to drugs that treat diseases affecting fewer than 200,000 people, provides seven years' marketing exclusivity from the date of approval. The ... |
ArQule, Daiichi Sankyo stop development of lung cancer drug
Reuters via Yahoo! Maktoob News Tue, 02 Oct 2012 05:17 AM PDT
(Reuters) - Biotechnology company ArQule Inc and Japan's Daiichi Sankyo Co Ltd said they will discontinue a late-stage trial of their experimental lung cancer drug after an interim analysis showed it would not meet the main goal of improving overall survival. While the interim analysis showed a statistically significant improvement in progression-free survival of patients on the drug tivantinib ... |
Celgene's Abraxane meets main goal in melanoma trial
Reuters via Yahoo! Canada News Tue, 02 Oct 2012 05:12 AM PDT
(Reuters) - Celgene Corp said a late-stage trial of its cancer drug Abraxane met its main goal of improving the patient's time of survival without worsening skin cancer, when compared to standard chemotherapy. Abraxane is already approved to treat breast cancer. Melanoma is the deadliest and most aggressive form of skin cancer. About 132,000 new cases of melanoma are diagnosed each year globally ... |
| |
|
No comments:
Post a Comment